Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
Phase 3
348
about 2.3 years
18–65
1 site in CA
About this study
This trial is testing repurposed drug treatments for Long Covid in adults. Participants will take either pirfenidone, upadacitinib, or a placebo for 842 days to see if the drugs improve symptoms like fatigue and breathing. It aims to assess the safety and effectiveness of these treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Pirfenidone
- 2.Take Placebo for pirfenidone
- 3.Take Placebo for upadacitinib
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pirfenidone, upadacitinib
oral (Oral Tablet), oral (Oral Solution)
Primary: Symptom Burden Questionnaire (SBQ) Subscales
Secondary: Exercise capacity assessed by the 6-minute walk test (6MWT), General participant reported overall well-being using the Patient Reported Outcome Measurement Information System (PROMIS)-29 questionnaire, Safety and tolerability of the study drugs in participants with Long Covid, Worsening Long Covid Symptoms Measured by SBQ Subscales